曲美布汀及双歧三联活菌联合抗焦虑抑郁药治疗难治性腹泻型肠易激综合征的疗效观察

目的:观察曲美布汀及双歧三联活菌联合抗焦虑抑郁药氟哌噻吨美利曲辛片治疗伴有焦虑和(或)抑郁的难治性腹泻型肠易激综合征(RIBS-D)的临床疗效。方法:101例伴有焦虑和(或)抑郁的RIBS-D患者随机分为试验组(52例)与对照组(49例),两组均给予曲美布汀及双歧三联活菌,试验组加服氟哌噻吨美利曲辛片,对照组加服安慰剂,疗程4周。观察治疗前后两组患者症状严重程度、精神状态、生活质量的变化及药品不良反应。结果:试验组与对照组的总有效率分别为86.54%、12.24%(P<0.01);试验组焦虑及抑郁积分较对照组显著降低,生活质量积分较对照组显著升高,两者差异均有统计学意义(P<0.01);治疗过程中未发生严重不良事件。结论:曲美布汀及双歧三联活菌联合抗焦虑抑郁药氟哌噻吨美利曲辛片治疗伴有焦虑和(或)抑郁的RIBS-D患者,能明显改善其症状、焦虑抑郁状态及生活质量,且十分安全。

Efficacy Observation of Antidepressant Melitracen-flupentixol Tablet Combined with Trimebutine Maleate and Bifid Triple Viable for Refractory Diarrhea-predominant Irritable Bowel Syndrome

OBJECTIVE： To observe clinical efficacy of antidepressant Melitracen-flupentixol tablet combined with trimebutine maleate and bifid triple viable in the treatment of refractory diarrhea-predominant irritable bowel syndrome （RIBS-D） complicating with anxiety or depression. METHODS： 101 cases of RIBS-D complicating with anxiety or depression were randomly divided into trial group （52 cases） and control group （49 cases）. Both groups were given trimebutine maleate and bifid triple viable; trial group was additionally given Melitracen-flupentixol tablet and control group was additionally given placebo for 4 weeks. The severity, mental state, life quality and ADR were observed in 2 groups before and after treatment. RESULTS： After the treatment, the total effective rate of trial group was 86.54% and that of control group was 12.24% （P〈0.01）. Compared with control group, the HADS of trial group were decreased significantly, while the IBS-QOL were increased significantly; there was statistical signifi- cance （P〈0.01）. No severe ADR was observed during treatment. CONCLUSIONS： The antidepressant Melitracen-flupentixol tab- let combined with antidepressant Melitracen-flupentixol tablet combined with trimebutine maleate and bifid triple viable for RIBS-D can improve symptoms, mental status and life quality without significant adverse drug events.